Australis Scientific key facts
as of Oct 2026- Developer of a neural modulation technology intended to revolutionize the treatment of LUTS (lower urinary tract symptoms).
- Australis Scientific is valued at approximately $26.5M as of Oct 2026 (last reported valuation).
- It has raised $12.8M; the latest was Early Stage VC ($6.1M) in Nov 2025.
- Notable investors include MedTech Innovator, Harvard Innovation Launch Lab, 10XBeta, Butterworth Investments, NSW Medical Devices Fund — 6 tracked in total.
- Status: Privately Held (backing).
Australis Scientific's last reported valuation, Nov 2023. Nothing priced has surfaced since.
- ·Watch Australis Scientific: the Monday email on marks, rounds and moves
Australis Scientific funding rounds
No funding rounds for Australis Scientific are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Australis Scientific
6Australis Scientific valuation
Australis Scientific's last reported valuation was $26.5 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
Australis Scientific investors
6 investors are on record for Australis Scientific, including MedTech Innovator, Harvard Innovation Launch Lab, 10XBeta and Butterworth Investments.
About Australis Scientific
Developer of a neural modulation technology intended to revolutionize the treatment of LUTS (lower urinary tract symptoms). The company's smart patch technology treats patients' lower urinary tract symptoms, including frequency, urgency, and nocturia, enabling individuals to get treated with neuromodulation device therapy based on their symptoms.
- Sector
- Healthcare
- HQ
- Sydney, Australia
- Founded
- 2021
- Employees
- 7
- Website
- australisscientific.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.